Key result
Drug-eluting balloons achieve STEMI reperfusion but are linked to a ~38% MACE rate.
Why the study?
The role and safety of drug-eluting balloons in the treatment of acute STEMI patients remain under investigation.
Does drug-eluting balloon intervention reduce major adverse cardiac events in adults with acute STEMI?
Cohort (n=100)
No
Does drug-eluting balloon intervention reduce major adverse cardiac events in adults with acute STEMI?
While drug-eluting balloons effectively achieved myocardial reperfusion in acute STEMI, they were associated with a high rate of MACE (38%) and safety concerns.
DEB in STEMI warrants clinical caution given high MACE; leaves open efficacy versus standard therapy pending randomized trials.
Drug-eluting balloons (DEB) have emerged as a promising strategy for coronary revascularization, offering the capability to deliver anti-proliferative medicines directly to coronary arteries. Nevertheless, the exploration of their role in the acute STEMI context is now underway. Objective: To assess the efficacy of DEB in mitigating major adverse cardiac events (MACE) among individuals diagnosed with Acute ST-segment elevation myocardial infarction (STEMI) at the Peshawar Institute of Cardiology. The present study employed various methodologies to investigate the research question. A prospective cohort study was undertaken during a period spanning from September 2022 to June 2023, encompassing a sample size of 100 eligible participants. The study gathered data on the baseline characteristics of the participants, as well as the details of the DEB intervention. Additionally, safety outcomes were assessed and recorded. The study included statistical analyses to evaluate alterations in troponin and CK-MB levels following DEB intervention. During the follow-up period, many patient outcomes were documented, including MACE, occurrences of bleeding episodes, and instances of restenosis. The study's findings demonstrated noteworthy decreases in troponin and CK-MB levels following the DEB intervention, suggesting effective restoration of blood flow to the heart muscle. The study observed a significant decrease in troponin levels, from an initial mean of 12.7 ng/mL (±4.6) to a final mean of 5.3 ng/mL (±2.1) (p < 0.001). Similarly, CK-MB levels showed a significant reduction, with an initial mean of 42.3 U/L (±12.8) decreasing to a final mean of 20.5 U/L (±8.3) (p < 0.001). Nevertheless, there was a notable rise in MACE rates after the DEB intervention, as 38% of the individuals observed encountered MACE throughout the follow-up period. The safety concerns encompass hemorrhagic episodes, occurring in 10% of cases, and restenosis observed in 14% of cases. In conclusion, DEB has shown effectiveness in attaining myocardial reperfusion. However, the observed rise in MACE rates and safety concerns emphasize the intricate nature of DEB utilization in cases of acute STEMI. Additional investigation is required to enhance the process of selecting patients and refining procedure approaches within this particular environment.
No takes yet. Share an insight, caveat, or question.
JAN et al. (2023) conducted a cohort in Acute ST-segment elevation myocardial infarction (STEMI) (n=100). Drug-eluting balloons (DEB) was evaluated on Major adverse cardiac events (MACE). Drug-eluting balloon intervention in acute STEMI patients achieved successful myocardial reperfusion but was associated with a 38% rate of major adverse cardiac events during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: